Health Minister Hsueh Jui-yuan (薛瑞元) said Wednesday the ministry's commissioning of Choice Pharma Taiwan to conduct Phase 2 clinical trials of the locally manufactured Medigen COVID-19 vaccine predated a merger between Choice Pharma's parent company and a Shanghai-based firm, amid controversy over possible Chinese involvement in the trials.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Taiwan conducts M1A2T tank live-fire drill
07/10/2025 11:59 AM - Politics
U.S. introduces bill to combat China's sabotage of Taiwan's underseas cables
07/10/2025 11:13 AM - Society
Taiwan headline news
07/10/2025 10:38 AM - Business
U.S. dollar up in Taipei trading
07/10/2025 10:29 AM - Society
Rain likely to continue across Taiwan on Thursday
07/10/2025 10:06 AM